Join us for How Far Would You Go to Prevent HIV? A Community Forum on PrEP Wednesday June 29th at the DC Center for the LGBT Community, 1318 U Street NW. Reception and light refreshments begin at 6:30 PM. The forum will start promptly at 7:00 PM.

Recent research results shows promise for a new HIV prevention strategy called pre-exposure prophylaxis or PrEP. PrEP involves HIV-negative people at risk for HIV using antiretroviral medications (ARVs) to reduce the risk of HIV infection.

The iPrEx trial results were released in November, 2010 and showed that in gay men, transgender women and other men who have sex with men, daily TDF/FTC (tenofovir disoproxyl fumarate plus emtricitabine also known as Truvada) reduced the risk of HIV by 44 percent. Additional studies are ongoing in other populations.

PrEP is not yet recommended for use. Given that iPrEx tested an already licensed drug, there is the potential for immediate, off-label use. In the US, the Centers for Disease Control and Prevention issued interim guidance on PrEP as an HIV prevention strategy for men who have sex with men.

Join us for a community forum and discussion on PrEP. There are strong opinions about PrEP and we hope to represent a wide variety of views and have a meaningful conversation that moves this discussion forward.